Bristol-Myers Squibb Company (BMY)
Investors Heavily Search Bristol Myers Squibb Company (BMY): Here is What You Need to Know
Zacks.com users have recently been watching Bristol Myers (BMY) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
The Magnificent 7 Dividend Stocks Every Passive Income Investor Should Own
24/7 Wall St. Insights Dividend stocks are starting to outperform in the second half of 2024.
Here's Why a Handful of Pharmaceutical Stocks Rose Wednesday
Shares of several drugmakers and biotechnology firms moved higher on Wednesday, notching some of the day's top performances in the S&P 500.
3 High-Yield Dividend Stocks With Payout Ratios Below 75%
Dividend stocks with less-than 75% payout ratios tend to outperform long term. The high-yield dividend payers AT&T, Bristol Myers Squibb, and Chevron stand out on this crucial measure.
2 Beaten-Down S&P 500 Dividend Stocks to Buy on the Dip and Hold Forever
The benchmark S&P 500 index is way up over the past year, but some of its dividend-paying components haven't participated in the gains. Bristol Myers Squibb's dividend offers a high yield that could rise on the back of several new drugs with soaring sales.
Bristol-Myers Squibb-backed Zenas BioPharma files for US IPO
Bristol-Myers Squibb-backed Zenas BioPharma has filed to go public in the United States, a regulatory filing showed on Thursday, underscoring improving investor appetite for new listings.
Bristol Myers' (BMY) HCC Combo Drug Accepted for FDA Review
Bristol Myers' (BMY) application seeking approval for the Opdivo/Yervoy combo to treat unresectable hepatocellular carcinoma gets accepted for FDA review.
Bristol Myers' (BMY) Breyanzi Label Expansion Application Validated
Bristol Myers' (BMY) application to expand Breyanzi's label for the treatment of adult patients with relapsed or refractory follicular lymphoma gets EMA validation.
3 High-Yield Dividend Stocks You Can Buy With $200 Now and Hold at Least a Decade
Bristol Myers Squibb doesn't sell anti-obesity drugs, but it can keep raising its dividend payout without them. Shares of Dow Inc. offer a yield above 5%, and there's a good chance the company can begin raising its payout again.
Where Will Bristol Myers Squibb Be in 5 Years?
Bristol Myers Squibb will face major losses of patent exclusivity by 2029. BMS has launched a number of brand-new approvals to replace older products.
All You Need to Know About Bristol Myers (BMY) Rating Upgrade to Buy
Bristol Myers (BMY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
BMY vs. VRTX: Which Stock Is the Better Value Option?
Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Bristol Myers Squibb (BMY) or Vertex Pharmaceuticals (VRTX). But which of these two stocks is more attractive to value investors?
